AU2016205138A1 - ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease - Google Patents

ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease Download PDF

Info

Publication number
AU2016205138A1
AU2016205138A1 AU2016205138A AU2016205138A AU2016205138A1 AU 2016205138 A1 AU2016205138 A1 AU 2016205138A1 AU 2016205138 A AU2016205138 A AU 2016205138A AU 2016205138 A AU2016205138 A AU 2016205138A AU 2016205138 A1 AU2016205138 A1 AU 2016205138A1
Authority
AU
Australia
Prior art keywords
inhibitor
membered
independently selected
sulfur
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016205138A
Other languages
English (en)
Inventor
Geraldine C. Harriman
H. James Harwood
Rosana Kapeller-Libermann
William F. Westlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Apollo LLC
Original Assignee
Gilead Apollo LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Apollo LLC filed Critical Gilead Apollo LLC
Publication of AU2016205138A1 publication Critical patent/AU2016205138A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016205138A 2015-01-09 2016-01-08 ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease Abandoned AU2016205138A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101726P 2015-01-09 2015-01-09
US62/101,726 2015-01-09
PCT/US2016/012673 WO2016112305A1 (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
AU2016205138A1 true AU2016205138A1 (en) 2017-07-13

Family

ID=56356482

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016205138A Abandoned AU2016205138A1 (en) 2015-01-09 2016-01-08 ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Country Status (13)

Country Link
US (2) US20180021341A1 (enExample)
EP (2) EP3597271A1 (enExample)
JP (2) JP2018501276A (enExample)
KR (1) KR20170102299A (enExample)
CN (1) CN107106873A (enExample)
AU (1) AU2016205138A1 (enExample)
BR (1) BR112017014341A2 (enExample)
CA (1) CA2972919A1 (enExample)
EA (2) EA201892625A1 (enExample)
HK (2) HK1243369A1 (enExample)
MX (1) MX2017008844A (enExample)
SG (1) SG11201705361PA (enExample)
WO (1) WO2016112305A1 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
ES2734713T3 (es) 2015-07-06 2019-12-11 Gilead Sciences Inc Moduladores Cot y métodos de utilización de los mismos
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
US20170166582A1 (en) * 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
SG10202104575WA (en) 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
JP2019537607A (ja) * 2016-11-10 2019-12-26 ガルメド リサーチ アンド ディベロップメント リミテッド 非アルコール性脂肪性肝疾患の患者における線維化の抑制
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CA3152584C (en) * 2016-11-10 2024-02-13 Galmed Research And Development Ltd. Treatment for fibrosis
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AU2018209006B2 (en) * 2017-01-22 2021-04-22 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
CN110431144B (zh) * 2017-03-24 2022-08-05 浙江海正药业股份有限公司 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途
US20180311244A1 (en) * 2017-03-28 2018-11-01 Gilead Sciences, Inc. Methods of treating liver disease
ES2982801T3 (es) * 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
EP3609496A1 (en) * 2017-04-12 2020-02-19 Gilead Sciences, Inc. Methods of treating liver disease
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
EP3609523B1 (en) * 2017-04-24 2022-03-02 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
US20200129511A1 (en) * 2017-06-19 2020-04-30 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash
WO2019015583A1 (en) * 2017-07-17 2019-01-24 Nanjing Ruijie Pharmatech Co., Ltd. NOVEL COMPOUNDS AND THEIR USES AS ACC INHIBITORS
EP3660023B1 (en) * 2017-07-26 2023-03-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Thienopyrimidinedione compounds as acc inhibitors and use thereof
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
US11542256B2 (en) 2017-09-03 2023-01-03 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
US11033601B2 (en) * 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
CN111182904A (zh) * 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
AU2019216264B2 (en) 2018-01-31 2023-08-31 Heparegenix Gmbh Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US20210113561A1 (en) * 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20210002573A (ko) * 2018-04-24 2021-01-08 주식회사 피에이치파마 간 질환에 호중구 엘라스타제 저해제의 사용
WO2019243315A1 (en) 2018-06-21 2019-12-26 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
SG11202012732UA (en) 2018-07-16 2021-02-25 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
JP7161605B2 (ja) 2018-08-31 2022-10-26 ファイザー・インク Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ
CA3111025C (en) * 2018-09-06 2023-10-31 Galmed Research And Development Ltd Combination therapy for the treatment of liver disease
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
AU2019385438A1 (en) * 2018-11-20 2021-05-27 The National Institutes of Pharmaceutical R&D Co., Ltd. Spiro compound and medical uses thereof
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2020208205A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN113924303B (zh) * 2019-07-02 2023-10-20 广东东阳光药业股份有限公司 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用
JP7629442B2 (ja) 2019-07-29 2025-02-13 ヘパリジェニックス ゲーエムベーハー 肝臓再生を促進または肝細胞死を縮減もしくは防止するためのヘテロアリール置換ピラゾロ－ピリジンタンパク質キナーゼ阻害剤
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN110628810B (zh) * 2019-08-13 2022-06-28 浙江大学 一种提高植物光合效率的方法
CN114340632B (zh) * 2019-08-30 2024-09-17 赛特瑞恩股份有限公司 用于治疗或预防非酒精性脂肪性肝炎（nash）的药物组合物
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
CA3164361A1 (en) 2020-01-15 2021-07-22 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
EP4126862B1 (en) 2020-04-02 2025-05-21 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR20230013126A (ko) 2020-05-21 2023-01-26 시오노기 앤드 컴파니, 리미티드 지방성 간질환의 치료용 의약
EP4000616A1 (en) * 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
ES3061522T3 (en) 2021-03-29 2026-04-06 Gilead Sciences Inc Khk inhibitors
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2023034381A1 (en) * 2021-08-31 2023-03-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Quantitative systems pharmacology methods for identifying therapeutics for disease states
WO2023047203A1 (en) * 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
JPWO2023090411A1 (enExample) 2021-11-19 2023-05-25
EP4731212A1 (en) * 2023-06-20 2026-04-29 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
KR20250155468A (ko) * 2024-04-22 2025-10-30 연세대학교 원주산학협력단 CCR2 억제제와 TGF-β 수용체 억제제의 병용투여를 통한 대사이상관련 지방간염 치료 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155611A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
MX370976B (es) * 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
AU2014262636A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
EP2994128B1 (en) 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
AU2014262638A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof

Also Published As

Publication number Publication date
BR112017014341A2 (pt) 2018-03-27
HK1243369A1 (zh) 2018-07-13
EP3242722A4 (en) 2018-07-11
WO2016112305A1 (en) 2016-07-14
CA2972919A1 (en) 2016-07-14
HK1246232A1 (zh) 2018-09-07
EP3242722A1 (en) 2017-11-15
JP2020109130A (ja) 2020-07-16
US20180021341A1 (en) 2018-01-25
MX2017008844A (es) 2018-03-14
SG11201705361PA (en) 2017-08-30
EA201791258A1 (ru) 2017-12-29
JP2018501276A (ja) 2018-01-18
EP3597271A1 (en) 2020-01-22
KR20170102299A (ko) 2017-09-08
EA201892625A1 (ru) 2019-07-31
CN107106873A (zh) 2017-08-29
US20190381045A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
US20190381045A1 (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
US11963961B2 (en) Combination therapy comprising an ACC inhibitor
US20220220148A1 (en) Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
CN104254325A (zh) 双胍组合物和治疗代谢性病症的方法
AU2010200722A1 (en) Methods of treating non-painful bladder disorders using Alpha2Delta subunit calcium channel modulators
KR20200131812A (ko) 대사 질병을 치료하기 위한 조성물 및 방법
HK40021469A (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application